KYMR — Kymera Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $6.38bn
- $5.54bn
- $39.21m
Annual cashflow statement for Kymera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -100 | -155 | -147 | -224 | -311 |
| Depreciation | |||||
| Non-Cash Items | 30.8 | 36.4 | 37.9 | 46 | 54.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -61.9 | -37.6 | 2.68 | -24 | 15.3 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -129 | -153 | -103 | -195 | -233 |
| Capital Expenditures | -1.6 | -2.84 | -34.5 | -12.8 | -1.45 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -98.2 | 23.4 | 174 | -391 | -520 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -99.8 | 20.5 | 140 | -404 | -521 |
| Financing Cash Flow Items | 1.95 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 250 | 153 | 4.19 | 609 | 991 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 21.5 | 20.4 | 41.3 | 10.3 | 237 |